Omer H. Elmadbouh

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).”.

Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4192

N/A

0DataRank · unranked

6 citations

Zachariah Brown, Sheila Linden, Christina Rodriguez, Omer H. Elmadbouh, Jonathan A. Pachter +9 more

Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells

Free Radical Biology and Medicine(2024)10.1016/j.freeradbiomed.2024.01.003

N/A

0DataRank · unranked

22 citations

Adrian Lim, Omer H. Elmadbouh, Mouad Edderkaoui, Arsen Osipov, Angela Mathison +5 more